Preaxial polydactyly of fingers

Summary

Preaxial polydactyly of fingers (MONDO:0017425) is a disease. A subtype of non-syndromic polydactyly — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	preaxial polydactyly of fingers
Mondo ID	MONDO:0017425
OMIM	174400
Orphanet	294939
ICD-11	1066753144
UMLS	C0345354
MedGen	87498
GARD	0012767
Is cancer (heuristic)	no

Also known as: preaxial polydactyly of hand

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › polydactyly › non-syndromic polydactyly › preaxial polydactyly of fingers

Related subtypes (9): polysyndactyly 4, synpolydactyly type 1, synpolydactyly type 2, postaxial polydactyly of fingers, central polydactyly of fingers, Preaxial polydactyly of toes, megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome, postaxial polydactyly, mirror-image polydactyly

Subtypes (3): polydactyly of a biphalangeal thumb, polydactyly of a triphalangeal thumb, polydactyly of an index finger

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.